Gassel Adam D, Tobias Karen M, Egger Christine M, Rohrbach Barton W
Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN 37996, USA.
J Am Vet Med Assoc. 2005 Dec 15;227(12):1937-44. doi: 10.2460/javma.2005.227.1937.
To compare the effectiveness of preoperative PO and SC administration of buprenorphine and meloxicam for prevention of postoperative pain-associated behaviors in cats undergoing ovariohysterectomy.
Randomized controlled study.
51 female cats (4 to 60 months old; weight range, 1.41 to 4.73 kg [3.1 to 10.4 lb]).
Cats received 1 of 5 treatments at the time of anesthetic induction: buprenorphine PO (0.01 mg/kg [0.0045 mg/lb]; n = 10), buprenorphine SC (0.01 mg/kg; 10), meloxicam SC (0.3 mg/kg 10.14 mg/lb]; 10), meloxicam PO (0.3 mg/kg; 10), or 0.3 mL of sterile saline (0.9% NaCI) solution SC (control group; 11). Sedation scores and visual analog scale and interactive visual analog scale (IVAS) pain-associated behavior scores were assigned to each cat 2 hours before and at intervals until 20 hours after surgery.
Cats receiving meloxicam PO or SC had significantly lower IVAS scores (2.91 and 2.02, respectively), compared with IVAS scores for cats receiving buprenorphine PO (755). Pain-associated behavior scores for cats administered buprenorphine or meloxicam PO or SC preoperatively did not differ significantly from control group scores. Rescue analgesia was not required by any of the cats receiving meloxicam, whereas 3 of 10 cats receiving buprenorphine PO, 2 of 10 cats receiving buprenorphine SC, and 1 of 11 cats receiving the control treatment required rescue analgesia.
On the basis of pain-associated behavior scores, cats receiving meloxicam PO or SC before ovariohysterectomy appeared to have less pain after surgery than those receiving buprenorphine PO preoperatively.
比较术前口服和皮下注射丁丙诺啡与美洛昔康预防母猫卵巢子宫切除术后疼痛相关行为的效果。
随机对照研究。
51只雌性猫(4至60月龄;体重范围1.41至4.73千克[3.1至10.4磅])。
猫在麻醉诱导时接受5种治疗中的1种:口服丁丙诺啡(0.01毫克/千克[0.0045毫克/磅];n = 10)、皮下注射丁丙诺啡(0.01毫克/千克;10只)、皮下注射美洛昔康(0.3毫克/千克[0.14毫克/磅];10只)、口服美洛昔康(0.3毫克/千克;10只)或皮下注射0.3毫升无菌生理盐水(0.9%氯化钠)溶液(对照组;11只)。在手术前2小时及术后至20小时期间每隔一段时间对每只猫进行镇静评分以及视觉模拟评分和交互式视觉模拟评分(IVAS)疼痛相关行为评分。
与口服丁丙诺啡的猫的IVAS评分(7.55)相比,口服或皮下注射美洛昔康的猫的IVAS评分显著更低(分别为2.91和2.02)。术前接受丁丙诺啡或美洛昔康口服或皮下注射的猫的疼痛相关行为评分与对照组评分无显著差异。接受美洛昔康的猫均无需急救镇痛,而接受口服丁丙诺啡的10只猫中有3只、接受皮下注射丁丙诺啡的10只猫中有2只以及接受对照治疗的11只猫中有1只需要急救镇痛。
根据疼痛相关行为评分,卵巢子宫切除术前接受口服或皮下注射美洛昔康的猫术后疼痛似乎比术前接受口服丁丙诺啡的猫更少。